Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesAssociation between the use of serotonin receptor 2A-blocking antidepressants and joint disorders
Arthritis Care and Research , 09/30/09
Kling A et al. – Joint disorders were considerably more frequently reported ADRs of 5-HT2A-blocking antidepressants than of other comparable drugs, suggesting a possible association between the use of 5-HT2A-blocking antidepressants and joint disorders.
Methods- Retrospective study
- In the Swedish material, the 5-HT2A antagonists were 45 times more often reported to give joint ADRs when related to sales figures and compared with the selective serotonin reuptake inhibitors
- Joint disorders constituted 6.6% of the total number of reports of possible ADRs for the three 5-HT2A-blocking substances mianserin, mirtazapine, and nefazodone compared with 0.5% for the SSRIs; in the WHO material, the joint disorders constituted 1.3% of all ADRs for the 5-HT2A-blocking antidepressants and 0.6% for the SSRIs
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Plasma level of myeloperoxidase in children with juvenile idiopathic arthritis (a pilot study)
Central European Journal of Medicine, 11/25/09
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Osteoporosis International, 11/25/09
Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis
International Journal of Rheumatic Diseases, 11/25/09
Sponsor
Article Search
Sponsor